Piper Sandler Reiterates Overweight Rating on Global Blood Therapeutics (GBT)
Tweet
Share
E-mail
Get Alerts GBT Hot Sheet
Price: $68.49 --0%
Rating Summary:
12 Buy, 15 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 18
Rating Summary:
12 Buy, 15 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 18
Join SI Premium – FREE
Piper Sandler analyst Danielle Brill reiterated an Overweight rating and $120.00 price target on Global Blood Therapeutics (NASDAQ: GBT). Brill believes that GBT is poised to realize Oxbryta's full potential in sickle cell disease. At the current valuation Brill sees opportunity for further upside as the Oxbryta launch moves forward and its "blockbuster potential is realized."
For an analyst ratings summary and ratings history on Global Blood Therapeutics click here. For more ratings news on Global Blood Therapeutics click here.
Shares of Global Blood Therapeutics closed at $68.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Taylor Devices, Inc. (TAYD) to Buy
- BMO Capital Starts Semtech Corp. (SMTC) at Outperform
- Walmart (WMT) PT Lowered to $115 at Wolfe Research
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
